The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. Sales of the vaccine ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Pfizer’s PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, ... the FDA approved MRNA’s mResvia for use in high-risk adults aged 18 ...

Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, ... and the FDA is expected to make a decision on that application by June 12.